Figure 3.

Modification of randomized treatment effects of ACE inhibitor–based therapy on the risk of major clinical outcomes according to short-term changes in serum potassium after treatment initiation. Short-term changes in serum potassium were defined on the basis of the measurement made 3 weeks after initiating ACE inhibitor–based therapy. White diamonds indicate the HRs for subgroups defined by short-term change in serum potassium. Black diamonds indicate the HRs of overall randomized participants of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial (n=11,140). Active indicates perindopril-indapamide.